MITOKININ
Mitokinin is operates in the healthcare industry focusing on biotechnology business. It launches medicinal chemistry effort to generate kinetin analogs optimized for activating PINK1. It plans to develop the analog or optimized variants to treat Parkinson's disease.
MITOKININ
Industry:
Biotechnology Health Care Life Science
Founded:
2017-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.mitokinin.com
Total Employee:
11+
Status:
Active
Contact:
(347) 668-8061
Total Funding:
5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt WordPress Wordpress Plugins Nginx Sitelinks Search Box Euro
Similar Organizations
BALX Holdings
Balx Holdings operates in the healthcare industry focusing on biotechnology business.
Centrexion
Centrexion operates in the healthcare industry, focusing on the biotechnology business.
Kytopen
Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Orionis Biosciences
Orionis Biosciences operates in the healthcare industry focusing on biotechnology business & innovation.
Patara Pharma
Patara Pharma operates in the healthcare industry focusing on the biotechnology business.
Rocket Pharmaceuticals
Rocket Pharmaceuticals Ltd. operates in the healthcare industry focusing on biotechnology business.
Sidero Bioscience
Sidero Bioscience operates in the healthcare industry focusing on biotechnology business.
Symic Biomedical
SYMIC Biomedical operates in the healthcare industry focusing on biotechnology business.
Tetherex Pharmaceuticals
Tetherex Pharmaceuticals operates in the healthcare industry focusing on biotechnology business.
Vetica Labs
Vetica Labs is operates in the healthcare industry focusing on biotechnology business.
Current Employees Featured
Founder
Investors List
Mission BioCapital
Mission BioCapital investment in Series A - Mitokinin
Official Site Inspections
http://www.mitokinin.com
- Host name: 159.180.132.176
- IP address: 159.180.132.176
- Location: North Chicago United States
- Latitude: 42.325
- Longitude: -87.8561
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60064
More informations about "Mitokinin"
Mitokinin is now part of AbbVie | AbbVie
Mitokinin is now part of AbbVie. We discover and develop innovative medicines for tomorrow, while helping people live better lives today. Read the announcement. Neuroscience. We’re delivering science that takes us closer to …See details»
Mitokinin - Crunchbase Company Profile & Funding
Mitokinin may be growing as it has been acquired by a larger pharmaceutical company, AbbVie, which is a significant event indicating expansion and increased market presence. The acquisition by a major player in the healthcare industry …See details»
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further ...
Oct 5, 2023 Under the terms of the agreement, AbbVie will pay Mitokinin shareholders $110 million at closing for the acquisition of Mitokinin. Mitokinin shareholders remain eligible for …See details»
Mitokinin Company Profile | Management and Employees List
Mitokinin Profile and History. Mitokinin is a discovery-stage biotechnology company developing PINK1 targeted therapeutics for the treatment of neurodegenerative and mitochondrial …See details»
Mitokinin - Company Profile - Tracxn
Dec 6, 2024 Mitokinin - PINK1-targeted therapies for mitochondria-associated diseases (familial form of Parkinson's Disease). Acquired by AbbVie. Raised a total funding of $9.53M over 2 …See details»
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further ...
Oct 5, 2023 Mitokinin was founded in 2013 based on technology discovered by scientific co-founders Nicholas Hertz and Kevan Shokat at UCSF. Investors include Mission BioCapital, …See details»
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, …See details»
AbbVie acquires Mitokinin in its Neuroscience pipeline
Oct 16, 2023 Mitokinin’s lead candidate, MTK-458, is a selective activator of Pten induced kinase 1 (PINK1). ... MedNess is a part of STEMPeers® which is a 501(c)(3) organization registered in PA as PhD Career Support Group. The …See details»
Mitokinin - MitoWorld
Mitokinin has combined a genetically validated target, a class of potent, highly selective small molecules, and a world-class scientific team to tackle the most critical unmet medical need of …See details»
Mitokinin, Inc., Enters into Purchase Right Agreement …
SAN FRANCISCO, March 2, 2021 /PRNewswire/ -- Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of neurodegenerative diseases, announced today that ...See details»
Mitokinin - Updates, News, Events, Signals & Triggers - Crunchbase
Organization. Mitokinin . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Growth Insight Details. Powered by AI . Edit Growth …See details»
Mitokinin Company Profile - Office Locations, Competitors ... - Craft
Mitokinin is a company that delivers drugs addressing neurodegenerative diseases. It focuses on small molecule therapeutics that specifically increase the activity of active-form PINK1. The …See details»
Mitokinin Company Profile 2024: Valuation, Investors ... - PitchBook
Mitokinin General Information Description. Developer of a small molecule therapeutics designed to increase the activity of active-form PINK1. The company offers compounds that do not …See details»
Mitokinin, Inc. Company Profile | San Francisco, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Mitokinin, Inc. of San Francisco, CA. Get the latest business insights from Dun & Bradstreet.See details»
Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie
Mar 2, 2021 Read original article at PRNewswire. SAN FRANCISCO, March 2, 2021 /PRNewswire/ — Mitokinin, Inc., a biotechnology company developing PINK1-targeted …See details»
Mitokinin - Overview, News & Similar companies | ZoomInfo.com
Oct 5, 2023 Mitokinin, Inc., Enters into Purchase Right Agreement with AbbVie Mitokinin, Inc., a biotechnology company developing PINK1-targeted therapeutics for the treatment of …See details»
AbbVie to Acquire Mitokinin, Strengthening Neuroscience Pipeline
Oct 5, 2023 Under the terms of the agreement, AbbVie will pay Mitokinin shareholders $110 million at closing for the acquisition of Mitokinin. Mitokinin shareholders remain eligible for …See details»
Mitokinin - Overview, News & Similar companies | ZoomInfo.com
Mitokinin is a discovery-stage biotechnology company developing PINK1 targeted therapeutics for the treatment of neurodegenerative and mitochondria l diseases. Mitokinin's lead program …See details»
Mitokinin - VentureRadar
Mitokinin has combined a genetically validated target, a class of potent, highly selective small molecules, and a world-class scientific team to tackle the most critical unmet medical need of …See details»
Mitokinin - Longevity List
Mitokinin’s lead candidate, MTK-458, has been extensively validated in in vitro and in vivo models of Parkinson’s disease. IND enabling studies are currently underway, and an IND filing is …See details»